Integrity Applications reports high clinical accuracy in GlucoTrack study
Integrity Applications released data from a study of its GlucoTrack non-invasive glucose measuring device for type 2 diabetes patients, touting high clinical accuracy amongst all participants.
The study evaluated the accuracy of the GlucoTrack device in 172 adults with type 2 daibetes who were prescribed 1 or more medications for major medical conditions associated with diabetes, the Wilmington, Del.-based company said.
Results from the study indicated that the GlucoTrack device showed comparable clinical and numerical accuracies amongst all participants with between 97.5% and 99.2% in the clinically acceptable A and B zones of the conensus error grid. All medication groups reported clinical accuracy above 72.5% in the A zone, and there was no noted statistical difference in mean and median aboslute relative difference between med groups.
“Adults with diabetes are significantly more likely to develop high blood pressure and high cholesterol, as well as have a higher risk for developing blood clots. The medications used to address these medical conditions, alongside with common diabetes medications, can have an impact on rapid glucose excursion and tissue hydration levels, which can lead to inaccuracies in both invasive and non-invasive glucose monitoring technologies. The results of this study gives us confidence that GlucoTrack provides accurate non-invasive glucose measurements independent of different medication regimes, making it an ideal tool for glucose monitoring in type 2 diabetes,” senior research engineer & study author Amit Rozner said in a prepared statement.
“Integrity Applications is committed to ensuring the development of an accurate and non-invasive glucose monitoring device suitable for people with type 2 diabetes, as well as those with prediabetes. A recent review of 27 approved meters demonstrated that more than 40% of them failed to meet the ISO 15197:2003 standards, in which they had received approval. These subpar performances might result from medications, test strips, sensors, and less than ideal measurement techniques. We are proud to have designed GlucoTrack to counteract these everyday challenges that can severely impact accuracy, while at the same time offer a revolutionary approach to diabetes management that goes beyond a better blood test,” CEO John Graham said in a press release.